Bacterial endotoxin-lipopolysaccharide role in inflammatory diseases: An overview.
Level 5 - mechanism / opinion, no new human data
Narrative review detailing biological mechanisms without original clinical or empirical data.
PubMed 40666174 · doi:10.22038/ijbms.2025.82302.17799
What was done
This narrative review synthesized literature on the molecular mechanisms through which the Gram-negative bacterial endotoxin lipopolysaccharide (LPS) activates innate immunity, triggers local and systemic inflammation, and contributes to acute and chronic disease states, as well as potential downstream therapeutic targets.
What was found
The abstract reports no empirical data, sample sizes, or quantitative effect estimates. It qualitatively describes LPS acting as a pathogen-associated molecular pattern (PAMP) that stimulates immune and non-immune cells, upregulates inflammatory mediators, and contributes to septic shock, neurodegenerative diseases, cardiovascular diseases, and cancer via pathways involving TLR4, NLRP3, HMGA1, MAPK, and NF-kB.
Why it matters
Understanding the cellular and molecular pathways of LPS-induced inflammation helps map potential therapeutic targets for mitigating chronic inflammatory and degenerative diseases.
Limits
The paper is a non-systematic narrative review with no primary experimental or clinical data reported in the abstract. It lacks quantitative synthesis, risk of bias assessment of included studies, and direct evaluation of clinical drug efficacy.
Cited by
- supports Toll-like receptors on innate immune cells recognize specific patterns such as gut bacterial lipopolysaccharides.